Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva/Ivax Merger Gets FTC OK Pending Divestitures

This article was originally published in The Pink Sheet Daily

Executive Summary

Par and Barr will acquire 15 of the companies’ generic offerings.

You may also be interested in...



Watson/Actavis Merger Requires Near Record Divestiture; Sandoz, Par Pick Up 18 Products

The required divestitures are quite significant relative to the size of the transaction: this is the second-largest divesture, but only the fifth-largest merger of generic firms.

Teva Incoming CEO Yanai To Take The Helm In First Half 2007

Teva appoints CEO Makov’s successor, the leader of a generic crop protection chemicals firm, from outside pharma.

Teva Incoming CEO Yanai To Take The Helm In First Half 2007

Teva appoints CEO Makov’s successor, the leader of a generic crop protection chemicals firm, from outside pharma.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS063078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel